Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of NYU Langone Health.

    Client Virtual Booth

    NYU LANGONE HEALTH

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    NYU Langone Health
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    550 First Avenue New York, NY 10016
    Telephone
    Telephone
    646-929-7870
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://nyulangone.org/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/nyulangonehealth/
    Twitter
    Twitter
    https://twitter.com/nyulangone

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    ANANDA Scientific Announces FDA Approval of the IND for a Clinical Trial exploring treatment of Social Anxiety Disorder (SAD)

    Details:

    Nantheia ATL5, an oral therapy containing 100mg of cannabidiol per capsule, features proprietary delivery technology (Liquid Structure) touted as enhancing the effectiveness and stability of cannabidiol.


    Lead Product(s): Cannabidiol

    Therapeutic Area: Psychiatry/Psychology Product Name: Nantheia

    Highest Development Status: Phase IIProduct Type: Small molecule

    Recipient: Ananda Scientific

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 30, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Orcosa Comments on Positive Results of NYU Langone’s Phase 1/2 Clinical Trial Utilizing ORAVEXX

    Details:

    On the first day after surgery, patients receiving ORAVEXX (cannabidiol, CBD), experienced on average 23% less pain as measured by the Visual Analog Scale (VAS) pain score compared to patients receiving the placebo.


    Lead Product(s): Cannabidiol

    Therapeutic Area: Neurology Product Name: Oravexx

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Recipient: Orcosa

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 25, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    famar-2024-07-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search